10 lessons on in vivo CAR-T cell therapies
This summer I came across Jan Fabre’s fabulous bronze sculpture Man Measuring the Clouds (right) in Japan, of all places. It represents humanity’s ambition, idealism, and the pursuit of impossible goals.
The artwork depicts a life sized bronze figure of a man, often thought to be modelled after Fabre’s late brother, standing on a tall ladder and reaching upwards with a measuring rod as if trying to measure the sky. The piece captures a blend of optimism, futility, and persistence in the face of unattainable aspirations.
Similarly, we might consider the concept of tackling a variety of complex diseases from cancer and cardiac fibrosis to various genetic disorders with a tiny cell therapy involving a sample of just few millilitres seems equally apt and fitting.
Is it truly impossible though?
In our latest post, we argue no it’s not – and may actually be much closer to reality than many people realise. What seemed like something on the distant horizon is likely to soon see not one, but multiple clinical trials opening up in other indications beyond blood cancers involving several cell therapy companies.
Following on from an inspiring talk this week, we offer 10 important lessons to think about and be challenged by – because the old yardsticks may well be a’changing sooner rather than later…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers